IP Library Granted Patent US 10,143,676
Granted Patent B2
US 10,143,676 · App. 15/357,171 · Granted Dec 4, 2018

Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders

Inventors: Susan E. Dubé (Carlsbad, CA); Neil B. Kavey (Chappaqua, NY)
Assignees: Pernix Sleep, Inc.; ProCom One, Inc.
A61K31/335
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,143,676
App. No.
15/357,171
Granted
Dec 4, 2018
Kind
B2
Abstract

The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders.

Claims (22)

1. A method for treating sleep maintenance insomnia characterized by fragmented sleep during the 8 th hour of sleep, the method comprising:

administering a dosage of doxepin or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given 8 hour period of desired sleep, the patient experiences fragmented sleep during the final 60 minutes of said period, wherein the dosage of doxepin or salt thereof is between about 0.1 and about 6 mg, wherein the doxepin or salt thereof is a geometric isomer mixture containing about 88.3% to about 100.0% of the trans-(E) isomer or is 100% trans-(E) isomer, and wherein the dosage is administered prior to the start of the sleep period.

2. The method of claim 1 , wherein said geometric isomer mixture contains more than 3% of the trans-(E) isomer.

3. The method of claim 1 , wherein said geometric isomer mixture contains more than 95% of the trans-(E) isomer.

4. The method of claim 1 , wherein said geometric isomer mixture contains more than 98% of the trans-(E) isomer.

5. The method of claim 1 , wherein said geometric isomer mixture contains more than 99% of the trans-(E) isomer.

6. The method of claim 1 , wherein said geometric isomer mixture contains at least 99.5% or 99.9% of the trans-(E) isomer.

7. The method of claim 1 , wherein the dosage is about 1 to about 6 milligrams.

8. The method of claim 1 , wherein the dosage is about 1 milligram.

9. The method of claim 1 , wherein the dosage is about 3 milligrams.

10. The method of claim 1 , wherein the dosage is about 6 milligrams.

11. A method for treating sleep maintenance insomnia characterized by early awakenings during the 8 th hour of sleep, the method comprising:

administering a dosage of doxepin or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given 8 hour period of desired sleep, the patient experiences early awakenings during the final 60 minutes of said period, wherein the dosage of doxepin or salt thereof is between about 0.1 and about 6 mg, wherein the doxepin or salt thereof is a geometric isomer mixture containing about 88.3% to about 100.0% of the trans-(E) isomer or is 100% trans-(E) isomer, and wherein the dosage is administered prior to the start of the sleep period.

12. The method of claim 11 , wherein said geometric isomer mixture contains more than 90% of the trans-(E) isomer.

13. The method of claim 11 , wherein said geometric isomer mixture contains more than 95% of the trans-(E) isomer.

14. The method of claim 11 , wherein said geometric isomer mixture contains more than 98% of the trans-(E) isomer.

15. The method of claim 11 , wherein said geometric isomer mixture contains more than 99% of the trans-(E) isomer.

16. The method of claim 11 , wherein said geometric isomer mixture contains at least 99.5% or 99.9% of the trans-(E) isomer.

17. The method of claim 11 , wherein the dosage is about 1 to about 6 milligrams.

18. The method of claim 11 , wherein the dosage is about 1 milligram.

19. The method of claim 11 , wherein the dosage is about 3 milligrams.

20. The method of claim 11 , wherein the dosage is about 6 milligrams.

Assignments (2)
SECURITY INTEREST Recorded Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2019
From: PERNIX SLEEP, INC.
To: CURRAX PHARMACEUTICALS LLC
Reel/Frame 049329/0730 →
Continuity (8)
Continuation 13692715 · Dec 3, 2012
Continuation 12535623 · Aug 4, 2009
Continuation In Part 12022788 · Jan 30, 2008
Continuation In Part 11804720 · May 18, 2007
Provisional Application 60898378 · Jan 30, 2007
Provisional Application 60801824 · May 19, 2006
Provisional Application 60833319 · Jul 25, 2006
Related Publication 20170065551A1 · Mar 9, 2017